Accéder au contenu
Merck

Gut/brain axis and the microbiota.

The Journal of clinical investigation (2015-02-18)
Emeran A Mayer, Kirsten Tillisch, Arpana Gupta
RÉSUMÉ

Tremendous progress has been made in characterizing the bidirectional interactions between the central nervous system, the enteric nervous system, and the gastrointestinal tract. A series of provocative preclinical studies have suggested a prominent role for the gut microbiota in these gut-brain interactions. Based on studies using rodents raised in a germ-free environment, the gut microbiota appears to influence the development of emotional behavior, stress- and pain-modulation systems, and brain neurotransmitter systems. Additionally, microbiota perturbations by probiotics and antibiotics exert modulatory effects on some of these measures in adult animals. Current evidence suggests that multiple mechanisms, including endocrine and neurocrine pathways, may be involved in gut microbiota-to-brain signaling and that the brain can in turn alter microbial composition and behavior via the autonomic nervous system. Limited information is available on how these findings may translate to healthy humans or to disease states involving the brain or the gut/brain axis. Future research needs to focus on confirming that the rodent findings are translatable to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, and Parkinson's disease.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Butyl 4-hydroxybenzoate, ≥99.0% (GC)
Supelco
Butylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Butyl 4-hydroxybenzoate, ≥99%
USP
Butylparaben, United States Pharmacopeia (USP) Reference Standard
Butyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard